FOCUS DAY MONDAY 20TH MAY, 2019
Improving Assays of Treg Cell Suppressor Function in Clinical Studies
9:00am - 12:00pm
As the development of regulatory T cell directed therapies move through the clinic, it is still challenging to gauge key facilitators of suppressor function and what is necessary for clinical efficacy. Quantifying Treg number by cell surface markers is not enough to determine its function.
Attendees will discuss:
- Various strategies to precisely and accurately quantify Treg in tissue and in peripheral blood
- Functional assays that demonstrate function in patients
- The advantages and limitations of proliferation assays
- Effector T cell response to Treg suppression in disease
Professor of Immunobiology
Yale School of Medicine
Dr. Hafler is the William S. and Lois Stiles Edgerly Professor and Chairman Department of Neurology, Yale School of Medicine and is the Neurologist-in-Chief of the Yale-New Haven Hospital. He graduated magna cum laude in 1974 from Emory University with combined B.S. and M.Sc. degrees in biochemistry, and the University of Miami School of Medicine in 1978. He then completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York.
Optimizing the Manufacturing Process to Improve Quality of Treg Cells at reasonable cost
1:00pm - 4:00pm
Regulatory T cells (Tregs) are currently in clinical trials for a variety of indications. Sources of Treg, Isolation of Tregs and Treg specificity are important considerations in the manufacturing process. Improving the yield of Treg isolation while remaining cost effective could be a key limiting factor to the commercial success of ex vivo Treg approaches.
Attendees will discuss:
- How phenotypic differences translate into functional differences
- Does a larger pool of alloreactive Treg in CB translate into a lower dose requirement for cell therapy
- Surface cell markers commonly used to isolate Tregs with high purity both PB and CB
- Treg isolation protocols
Chief Scientific Officer
Andrew M. Scharenberg, MD, is an Attending Physician at Seattle Children’s Hospital, a Professor in the Department of Pediatrics, and an Adjunct Professor in the Department of Immunology at the University of Washington School
of Medicine in Seattle. He presently serves as Chief Scientific Officer of Casebia Therapeutics in Cambridge, MA. Prior to joining Casebia, Dr. Scharenberg co-directed (with David Rawlings M.D.) the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. This work led to the development of a program in engineered regulatory T-cells, recently partnered with Casebia for the purpose of developing gene edited cell therapeutics.